https://orcid.org/0000-0001-7658-2834
References
- Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth. 2020;34:479–482. doi:10.1007/s00540-020-02755-1
- Kilpatrik GJ, Mclntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107:60–66. doi:10.1097/01.anes.0000267503.85085.c0
- Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo-and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam 8CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115:274–283. doi:10.1213/ANE.0b013e31823f0c28
- Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020;132(4):636–651. doi:10.1097/ALN.0000000000003103
- Worthington MT, Antonik LJ, Goldwater DR, et al. A phase Ib. dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117:1093–1100. doi:10.1213/ANE.0b013e3182a705ae
- Borkett KM, Riff DS, Schwartz HI, et al. A phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015;120:771–780. doi:10.1213/ANE.0000000000000548
- Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88:427–437. doi:10.1016/j.gie.2018.04.2351
- Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34:545–553.
- Zhang X, Li S, Liu J. Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial. BMC Anesthesiol. 2021;21:156. doi:10.1186/s12871-021-01373-y
- Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacokinetics of electroencephalogram effects. Anesthesiology. 2020;132(4):652–666. doi:10.1097/ALN.0000000000003102
- Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine and the respiratory and cardiovascular systems. Br J Pharmacol. 2008;155:52–61. doi:10.1038/bjp.2008.228
- Miyake W, Oda Y, Ikeda Y, et al. Electroencephalographic response following midazolam-induced general anesthesia: relationship to plasma and effect-site midazolam concentrations. J Anesth. 2010;24(3):386–393. doi:10.1007/s00540-010-0907-4
- Doi M. Remimazolam. J Jpn Soc Clin Anesth. 2014;34(7):860–866. Article in Japanese. doi:10.2199/jjsca.34.860
- Tsurumi K, Takahashi S, Hiramoto Y, et al. Remimazolam anaphylaxis during anesthesia induction. J Anesth. 2021;35:571–575. doi:10.1007/s00540-021-02934-8
- Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth. 2021;35:322. doi:10.1007/s00540-021-02915-x